5 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Carcinoma, Medullary: new trials by email Literature Review of Carcinoma, Medullary trials Research Report on Carcinoma, Medullary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC 68Ga-CTR-FAPI PET-CT guided surgery, investigator choice of surgery - Medullary Thyroid Carcinoma | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 150 | 2025-08-25 | 2026-02-03 |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-11-30 | 2024-01-05 | |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 291 | 2020-02-11 | 2026-03-19 |
| Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Anlotinib, Placebo - Medullary Thyroid Carcinoma | Phase 2 / Phase 3 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 91 | 2015-07-01 | 2019-05-21 |
| Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Patient outreach, Vandetanib - Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer | Phase 3 | Completed | Sanofi | 205 | 2011-02-25 | 2026-04-17 |
| Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer XL184, Placebo - Thyroid Cancer | Phase 3 | Completed | Exelixis | 330 | 2008-06-01 | 2021-04-20 |
| An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer ZD6474 (Vandetanib) - Thyroid Cancer | Phase 3 | Completed | Genzyme, a Sanofi Company | 331 | 2006-11-23 | 2025-09-24 |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism Parathyroid hormone testing, Serum calcium testing - Hypercalcemia, Familial Primary Hyperparathyroidism | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2006-05-09 | 2017-07-02 |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors 123I-meta-iodobenzylguanidine - Pheochromocytoma, Neuroblastoma | Phase 3 | Unknown | Vancouver Coastal Health | 2011-06-15 |
Thyroid Neoplasms (2) · Carcinoid Tumor (1) · Familial medullary thyroid carcinoma (1) · Gastrinoma (1) · Hypercalcemia (1) · Hyperparathyroidism 1 (1) · Insulinoma (1) · Multiple Endocrine Neoplasia (1) · Multiple Endocrine Neoplasia Type 2a (1) · Neoplasm Metastasis (1) · Neuroblastoma (1) · Paraganglioma (1) · Pheochromocytoma (1)
Adenocarcinoma (9) · Carcinoma (9) · Carcinoma, Neuroendocrine (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Ductal, Lobular, and Medullary (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Nerve Tissue (9) · Neuroectodermal Tumors (9) · Neuroendocrine Tumors (9) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms by Site (3) · Head and Neck Neoplasms (2)
vandetanib (4) · cabozantinib (2) · anlotinib (1) · pralsetinib (1) · selpercatinib (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Exelixis (1) · Genzyme, a Sanofi Company (1) · Hoffmann-La Roche (1) · Loxo Oncology, Inc. (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Sanofi (1) · Vancouver Coastal Health (1)
Canada (5) · Belgium (4) · Brazil (4) · China (4) · Germany (4) · India (4) · Italy (4) · Poland (4) · Russia (4) · South Korea (4) · Spain (4) · United States (4) · Australia (3) · Austria (3) · Czechia (3)
Daniel Worsley, MD (1) · Shaoyan Liu, MD (1)
PMID 22025146, PMID 24002501, PMID 29045520, PMID 34292174, PMID 35969032, PMID 37870969, PMID 38778111, PMID 39470165, PMID 39694978, PMID 40617171
2005 (1), 2019 (1)